 The purpose of this study is to determine if the combination of two new drugs, cetuximab Erbitux and bevacizumab Avastin can increase the effectiveness of treatment for head and neck cancer. Cetuximab has recently been approved by the FDA for head and neck cancer that is locally or regionally advanced when used in combination with radiation therapy. Cetuximab is also approved by the FDA for the treatment of colorectal cancer 